Investigational drug · Phase 2
GEN1042
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC).
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "GEN1042"
First trial start
2019
Sep 17, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GEN1042", any sponsor or status.
Conditions studied
As listed on its trial records.
- Malignant Solid Tumor
- Non-Small Cell Lung Cancer (NSCLC)
- Colorectal Cancer (CRC)
- Melanoma
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Pancreatic Ductal Adenocarcinoma (PDAC)
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Colorectal cancer · Melanoma · Pancreatic cancer · Head and neck cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "GEN1042" as an intervention, largest first.
- GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid TumorsActive, not recruiting
GenmabIndustry
NCT04083599 · 350 participants · Start Sep 17, 2019 · Primary completion Dec 30, 2025
Drug: GEN1042; Pembrolizumab and 7 more · For: Malignant Solid Tumor; Non-Small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC) and 3 more
Sites: Anchorage, Alaska; Los Alamitos, California; San Diego, California · 76 sites in all
GenmabIndustry
NCT05491317 · 13 participants · Start Mar 8, 2023 · Primary completion Aug 11, 2025
Drug: GEN1042; Pembrolizumab · For: Non-CNS Tumor
Sites: Lyon, France; Villejuif, France
- A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid TumorsActive, not recruiting
GenmabIndustry
NCT06057038 · 8 participants · Start Nov 24, 2023 · Primary completion Aug 2027
Drug: GEN1042; Pembrolizumab and 3 more · For: Malignant Solid Tumor
Sites: Kashiwa, Japan; Tokyo, Japan · 3 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- An Fc-inert mouse-human chimeric variant of DuoBody®-CD40x4-1BB exhibits in vivo antitumor activity and peripheral immune modulation.
Pilones K, Sette A, Bachu M, et al. · Oncoimmunology 2026
- Dose Selection for DuoBody®-CD40x4-1BB (GEN1042/BNT312) Using a mPBPK/RO Model Leveraging Preclinical and Clinical Data.
Bajaj G, Shchelokov D, Demin O, et al. · Clin Pharmacol Ther 2025
- A systematic review of antibody-drug conjugates and bispecific antibodies in head and neck squamous cell carcinoma and nasopharyngeal carcinoma: Charting the course of future therapies.
Jiménez-Labaig P, Rullan A, Hernando-Calvo A, et al. · Cancer Treat Rev 2024
- DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity.
Muik A, Adams 3rd HC, Gieseke F, et al. · J Immunother Cancer 2022
- Dual-Targeting Approach for CD40 and 4-1BB.
· Cancer Discov 2022
Also in development for Malignant Solid Tumor
- I-DXdDS-7300a, MK-2400Phase 317 trials
Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma
- ASKB589Phase 33 trials
AskGene Pharma, Inc. · Gastric Cancer, Gastroesophageal Cancer (GC), Malignant Solid Tumor
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.